Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty 100 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's has informed exchanges that the U.S. Securities and Exchange Commission (SEC) has concluded its investigation into allegations of improper payments to healthcare professionals in Ukraine and other countries, which could have violated the U.S. Foreign Corrupt Practices Act (FCPA). The matter, originally flagged through an anonymous complaint in 2019-2020, was voluntarily disclosed by the company to the SEC, U.S. Department of Justice (DOJ), and SEBI. After years of cooperation, the SEC has stated it does not intend to recommend any enforcement action against the company at this time. The standard SEC caveat applies — the closure is not an official exoneration, and the DOJ investigation status is not addressed in this update.
This is a significant positive development for Dr. Reddy's as it removes a major regulatory overhang that had been hanging over the stock since 2020. Shareholders can expect relief in the stock price, though a small amount of uncertainty may persist until the DOJ's position is also clarified.